Display options
Cite
Lee JH, Pidaparti RM, Atkinson GM, et al. Design of an implantable device for ocular drug delivery. J Drug Deliv. 2012;2012:527516doi: 10.1155/2012/527516.
Lee, J. H., Pidaparti, R. M., Atkinson, G. M., & Moorthy, R. S. (2012). Design of an implantable device for ocular drug delivery. Journal of drug delivery, 2012527516. https://doi.org/10.1155/2012/527516
Lee, Jae-Hwan, et al. "Design of an implantable device for ocular drug delivery." Journal of drug delivery vol. 2012 (2012): 527516. doi: https://doi.org/10.1155/2012/527516
Lee JH, Pidaparti RM, Atkinson GM, Moorthy RS. Design of an implantable device for ocular drug delivery. J Drug Deliv. 2012;2012:527516. doi: 10.1155/2012/527516. Epub 2012 Jul 18. PMID: 22919500; PMCID: PMC3418683.
Copy Download .nbib Format: NLM
Share it on

J Drug Deliv. 2012;2012:527516. doi: 10.1155/2012/527516. Epub 2012 Jul 18.

Design of an implantable device for ocular drug delivery.

Journal of drug delivery

Jae-Hwan Lee, Ramana M Pidaparti, Gary M Atkinson, Ramana S Moorthy

Affiliations

  1. Department of Mechanical and Nuclear Engineering, Virginia Commonwealth University, Richmond, VA 23284, USA.

PMID: 22919500 PMCID: PMC3418683 DOI: 10.1155/2012/527516

Abstract

Ocular diseases, such as, glaucoma, age-related macular degeneration (AMD), diabetic retinopathy, and retinitis pigmentosa require drug management in order to prevent blindness and affecting million of adults in USA and worldwide. There is an increasing need to develop devices for drug delivery to address ocular diseases. This study focuses on the design, simulation, and development of an implantable ocular drug delivery device consisting of micro-/nanochannels embedded between top and bottom covers with a drug reservoir made from polydimethylsiloxane (PDMS) which is silicon-based organic and biodegradable polymer. Several simulations were carried out with six different micro-channel configurations in order to see the feasibility for ocular drug delivery applications. Based on the results obtained, channel design of osmotic I and osmotic II satisfied the diffusion rates required for ocular drug delivery. Finally, a prototype illustrating the three components of the drug delivery design is presented. In the future, the device will be tested for its functionality and diffusion characteristics.

References

  1. Biomed Microdevices. 2009 Apr;11(2):503-8 - PubMed
  2. Chem Pharm Bull (Tokyo). 2004 Nov;52(11):1290-4 - PubMed
  3. Pharm Res. 2009 May;26(5):1197-216 - PubMed
  4. Biomed Microdevices. 2009 Oct;11(5):959-70 - PubMed
  5. J Pharm Sci. 1997 Sep;86(9):1040-5 - PubMed
  6. Adv Drug Deliv Rev. 2006 Nov 15;58(11):1164-81 - PubMed
  7. Invest Ophthalmol Vis Sci. 2000 Apr;41(5):961-4 - PubMed
  8. Vision Res. 2010 Mar 31;50(7):680-5 - PubMed
  9. N Engl J Med. 2008 Jun 12;358(24):2606-17 - PubMed
  10. Lancet. 2008 Nov 22;372(9652):1835-45 - PubMed
  11. Drug Discov Today. 2011 Mar;16(5-6):270-7 - PubMed
  12. Pharm Res. 2006 May;23(5):847-63 - PubMed
  13. Invest Ophthalmol Vis Sci. 2000 Oct;41(11):3569-75 - PubMed

Publication Types